Maxigen Biotech Inc. reported consolidated revenues results for the month and year to date ended December 2022. On a consolidated basis, revenues for December 2022 were approximately TWD 61.732 million, an increase of 50.30% over the same period in 2021.
Revenues for January through December 2022 totaled TWD 604.431 million, an increase of 18.06% compared to the TWD 511.976 million for the same period in 2021.